2005
DOI: 10.1615/intjmedmushrooms.v7.i3.890
|View full text |Cite
|
Sign up to set email alerts
|

Dissemination of Case Studies on Ganotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
8
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 0 publications
0
8
0
Order By: Relevance
“…Therefore, more advanced research is needed to enhance both growth and secondary metabolites contents in this plant. Plant in vitro culture could represent an attractive option to multiply the plant [22], and also to produce plant biomass and secondary metabolites in controlled environment [23][24][25]. Light is an important abiotic elicitor that could also affect different physiological processes such as growth and development [26].…”
Section: Introductionmentioning
confidence: 99%
“…Therefore, more advanced research is needed to enhance both growth and secondary metabolites contents in this plant. Plant in vitro culture could represent an attractive option to multiply the plant [22], and also to produce plant biomass and secondary metabolites in controlled environment [23][24][25]. Light is an important abiotic elicitor that could also affect different physiological processes such as growth and development [26].…”
Section: Introductionmentioning
confidence: 99%
“…[30] also showed that concomitant ligand binding usually is only partially competitive and may include allosteric effects. However, when analysing ligand–ligand displacement interactions, the possibility of displacement of ligand from one site to another site should be taken into account [31, 40]. …”
Section: Discussionmentioning
confidence: 99%
“…A large variety of oncolytic viral families have been investigated in various preclinical and clinical cancer studies [23]. These cover both single-stranded and double-stranded RNA and DNA viruses, including measles virus, vesicular stomatitis virus (VSV), reovirus, type 1 herpes simplex s (HSV-1), Newcastle disease virus (NDV), adenovirus, and poxviruses (vaccinia and myxoma viruses) [24][25][26][27][28][29][30][31][32][33]. As reviewed by Yang and colleagues, multiple viral and tumoral factors can impact OV therapy [24], but there are no general rules to predict the oncolytic efficiency of any OV with any target cancer, in part because the tumor microenvironment can vary widely, even within a single cancer patient.…”
Section: Oncolytic Viral Therapymentioning
confidence: 99%